RAW-LABS
11.2.2021 18:14:10 CET | Business Wire | Press release
RAW Labs , today announced it has completed a USD 5.5M pre-A funding round raising capital from new and existing investors to support the surge in demand for its revolutionary data management solution. The company also announced Lars Farnstrom as its new CEO.
The financing round was led by a group of investors specializing in investments of high growth technology companies and Investiere.ch. The funding will enable RAW Labs to accelerate the acquisition of large enterprise clients and continue investing in the expansion of the capabilities of its core NoDB data platform. Claude Honegger (former global CIO of Credit Suisse) and Pyrros Koussios (former private equity investor and senior executive at international technology companies) are joining the board of directors.
“We are excited that Lars has accepted the CEO role. His long experience in enterprise software from companies like Siebel Systems and C3.ai is a tremendous asset and will enable us to take RAW Labs to the next level,” said Ariel Luedi, one of the founding investors of RAW Labs and former CEO of SAP Hybris. Professor Anastasia Ailamaki, co-founder of RAW Labs, will continue as Chief Scientific Officer with the mission to strengthen the company’s research into groundbreaking data management technologies.
RAW Labs’ NoDB is a platform for data engineers, data scientists, and data analysts to seamlessly access, query, clean, and enhance heterogeneous data sources in near real time and transform them into high-value data products for consumption by analytical tools, ML-models, and enterprise applications.
What makes RAW NoDB unique is its revolutionary query engine, which unlike any other solution in the market uses Category Theory. This gives RAW the unique capability to query large and complex data sources at high performance without the need for any costly and time-consuming ETL/ELT preprocessing or integration with data sources.
“It’s a privilege to have a group of sophisticated investors who have proven experience in helping technology companies scale,” said Lars Farnstrom, CEO of RAW Labs. “Data drives digital transformation. We believe that by eliminating the artificial barrier between operational and analytical data, and by enabling this in record time and without any expensive integrations, RAW Labs can help companies accelerate their digital transformation. Just connect your data sources and start asking questions that will help you unlock new insights on how to reduce costs or increase sales.”
About RAW Labs
RAW Labs, an École Polytechnique Fédérale de Lausanne (EPFL) spinout, helps companies unlock the value of data by providing a single unified platform to effortlessly access and convert any data source into data products for new insights and better decision making, at a fraction of the time and cost of traditional solutions. RAW is available on premise, in the cloud, or in hybrid mode.
For more information, visit https://www.raw-labs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005738/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom